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a b s t r a c t
Enterotoxigenic E. coli (ETEC) and Shigella are enteropathogens causing significant global morbidity and
mortality, particularly in low-income countries. No licensed vaccine exists for either pathogen, but can-
didates are in development, with the most advanced candidates potentially approaching pivotal efficacy
testing within the next few years.
A positive policy recommendation for introduction of any vaccine, following licensure, depends on evi-
dence of vaccine cost-effectiveness and impact on morbidity and mortality. The mortality estimates for
these two pathogens have fluctuated over recent years, which has led to uncertainty in the assessment
of their relative public health importance for use in low and middle-income countries.
This paper summarizes the various ETEC and Shigella disease burden estimates, based on a review of
current literature and informal consultations with leading stakeholders in enteric disease modelling.
We discuss the factors that underpin the variability, including differences in the modelling methodology;
diagnostic tools used to ascertain diarrheal etiology; epidemiological setting; the data that are available
to incorporate; and absolute changes in the total number of diarrheal deaths over time. We consider the
further work that will strengthen the evidence needed to support future decision making with respect to
recommendations on the relative utility of these vaccines.
 2017 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Recent global estimates attribute more than a million deaths
per year to diarrhea across all age groups and approximately 4%
of total global disability-adjusted life years (DALYS) [1–3]. Despite
reductions in mortality, diarrheal morbidity remains high, and the
condition remains a major burden in low and middle income coun-
tries (LMICs) in Africa and Asia, where water quality and sanitation
are poor [4–7]. Shigella and ETEC are major causes of diarrhea in
infants and school-age children, as well as in adults and travelers
to endemic regions [8–13]. However, global mortality estimates
for these pathogens have fluctuated since 2010, and estimated
mortality rates are now lower than ever previously reported. There
is some debate as to whether development of stand-alone vaccines
against these pathogens is warranted, or whether combination
vaccine approaches, or other interventions, should be prioritized.
Both ETEC and Shigella are spread via fecal-oral transmission,
through contaminated food or water, and human-to-human con-
tact [14,15]. Household contacts of shigellosis cases may be partic-
ularly susceptible to infection, with possible transmission by
houseflies [16,17]. ETEC strains (producing heat-labile toxin [LT]
and/or heat-stable type toxin [ST]) produce fimbrial or non-
fimbrial adhesins that enable attachment to host epithelial cells,
allowing them to colonize the small intestine. They then release
LT and/or ST enterotoxins that disrupt electrolyte homeostasis,
leading to fluid loss and eventually secretory (watery) diarrhea
[18]. Both the human (STh) and porcine (STp) genotypes of ST
are associated with human disease [19]. Given the mechanism of
ETEC pathogenesis, development of vaccine candidates has focused
on presentation of appropriate colonization factor antigens (CFA)
adhesins and enterotoxins. However, at least 25 immunologically
distinct CFAs have been identified and it remains challenging to
overcome colonization factor and toxin heterogeneity [20,21].
Shigella spp. are invasive organisms causing both watery diar-
rhea and dysentery following internalization into specialized
endothelial (M) cells and activation of a cascade of immunological
responses that cause inflammation and ultimately destruction of
the bowel [22,23]. Watery diarrhea typically precedes dysentery
and results from the action of enterotoxins in the jejunum,
whereas bloody diarrhea results from invasion of the colonic
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epithelium. To date, four species and 49 serotypes have been iden-
tified that include S. dysenteriae (15 serotypes), S. flexneri (13 sero-
types), S. boydii (20 serotypes) and S. sonnei (1 serotype). The major
focus of vaccine development effort is directed to S. flexneri which
accounts for 60% of endemic disease in infants and children in
LMICs, whereas S. sonnei causes the majority of cases in industrial-
ized countries and is an important cause of travelers’ diarrhea.
Serotypes are defined based on the carbohydrate composition of
the surface O-antigen, and vaccine development approaches are
broadly based on serotype-specific targeting of these antigens, or
conserved antigens, such as invasion plasmid antigen (Ipa)
proteins [24].
Whole cell and subunit ETEC and Shigella vaccine candidates are
currently in clinical trials [22,24,25]. Distribution of strains, anti-
genic components, and disease severity differ between developed
countries and LMICs and can vary by age group [26,27]. The most
common diarrheagenic ETEC colonization factors include CFA/I,
CS3 and CS6, while the most common Shigella serotypes are S. flex-
neri 2a, 6, 3a, and S. sonnei [28,29]. The most advanced ETEC and
Shigella vaccine candidates include these components in the form
of killed whole cells [24,25,28] that may be suitable for combina-
tion [30].
Several studies have indicated repeated enteric infections can
be associated with long term sequelae and diseases, including mal-
nutrition, stunting, pneumonia and arthritis, in both LMICs and
developed countries [4,31–33]. The effects of these infections are
most profound in infants and school-age children, and can hinder
cognitive development, school performance, and economic stabil-
ity [34–36]. In addition, the rise of antibiotic resistance, and a
recent safety warning related to treatment with the antibiotic
Ciprofloxacin, further underscore the persisting unmet need for
effective vaccines against these pathogens [37,38].
Although ETEC and Shigella vaccine candidates are at least five
to 10 years from licensure, conclusions regarding the public health
need for vaccines based on currently available burden estimates
inform vaccine investment decision-making today, particularly
with respect to a potential combination vaccine [30]. Such deci-
sions impact critical components of vaccine development strategy,
including clinical and regulatory pathways, formulation, and pre-
sentation optimization. In addition, accurate disease burden esti-
mates provide baseline data to assess future vaccine impact, and
help identify clinical trial sites for rapid and appropriately powered
vaccine efficacy assessments. It is important, therefore, to under-
stand the underlying causes for the uncertainties and possible lim-
itations of Shigella and ETEC disease burden estimates.
2. Current disease burden estimates
Our discussion focuses on published ETEC and Shigella disease
burden estimates that are generally based either on secondary,
extrapolated information taken from systematic reviews, or
primary data directly gathered at community or clinic levels. The
Global Burden of Disease (GBD) Mortality and Causes of Death Col-
laborators, Child Health Epidemiology Reference Group/Maternal
Child Epidemiology Estimation (CHERG/MCEE), the Foodborne Dis-
ease Burden Epidemiology Reference Group (FERG), and other sec-
ondary analyses have based their conclusions on a combination of
systematic literature reviews, government vital records and verbal
autopsies, and modelling [1,2,10,14,39,40].
Estimates of mortality attributable to ETEC and Shigella depend
on the data sources used, geographical range, year of reporting,
case definitions, age groups, and methodology. For example, suc-
cessive iterations of the GBD estimates, from 2010 to 2015, used
modified methodology and new data inputs [1,2,39,40]. Conse-
quently, burden estimates vary and cannot be easily compared.
2.1. Estimates derived from systematic reviews and models
Table 1 shows recent estimates of ETEC and Shigella deaths in
children under five years. The most recently published estimates
from GBD are for the year 2015 [1,40], and from CHERG/MCEE
for the year 2011 [10]. In children under five years, the GBD
2015 analysis estimated Shigella deaths to be 54,905 (27,026–
94,731), in contrast to the CHERG/MCEE 2011 analysis of 28,000
(12,000–53,000). The under -five-years mortality estimate due to
ETEC was 23,649 (9,553–44,337) according to GBD in 2015, and
42,000 (20,000–76,000) according to CHERG/MCEE in 2011
[1,10,40]. Of note, estimated Shigella deaths in the GBD analyses
for the years 2013 and 2015, increased from 33,400 (24,900–
43,500) to 54,905 (27,026–94,731), respectively, whereas the esti-
mated number of ETEC deaths between the years remained similar
[1,39].
With respect to deaths at all-ages, the GBD estimate of annual
Shigella-attributable deaths decreased from 122,800 (97,400–
149,600) in the year 2010 to 73,900 (58,900–93,800) in 2013,
and subsequently increased to 164,300 (85,000–278,700) in 2015
[1,2,39]. Likewise, the ETEC mortality estimates have fluctuated
from 120,800 (95,700–147,600) in 2010 to 59,200 (44,200–
77,700) in 2013, followed by a comparatively more modest
increase to 74,100 (29,900–137,900) in 2015 (Table 2) [1,2,39].
However, the uncertainty intervals on these estimates are wide
and overlapping.
Contrary to GBD estimates, but in line with estimates published
by CHERG/MCEE, FERG estimates for overall ETEC mortality are
higher at all ages than for Shigella, at 73,857 (53,851–103,026) vs
65,796 (46,317–97,036), respectively [14]. Furthermore, the num-
ber of ETEC deaths specifically attributable to foodborne transmis-
sion are determined to be higher than that of Shigella at all ages
(Table 2: 26,170 (14,887–43,523) vs 15,156 (6,839–30,072),
respectively) with approximately half the burden occurring in
the under -five-year age group [14]. Both pathogens had a greater
number of illnesses among those over five years, but a greater
number of deaths among those under five. This was particularly
Table 1
Global Estimates of Deaths Among Children Under Five.
Study FERG [14]a CHERG/MCEE [10] GBD 2013 [39] GBD 2015 [1,40]
Year of publication 2015 2013 2015 2016
Time period of data collection 1990–2012 1990–2011 1990–2013 1980–2015
Year represented in data 2010 2011 2013 2015
Geographical range of estimates 194 countries Global 188 countries 195 countries and territories
Number of pathogens assessed 22 13 13 13
All-cause diarrheal deaths
(uncertainty range)
91,621 (62,442–132,707) 712,000 (491,000–1,049,000) 474,900 (398,100–545,000) 499,000 (447,000–558,000)
ETEC deaths (uncertainty range) 14,056 (7,045–26,784) 42,000 (20,000–76,000) 23,100 (17,000–30,400) 23,649 (9,553–44,337)
Shigella deaths (uncertainty range) 8,863 (3,250–20,925) 28,000 (12,000–53,000) 33,400 (24,900–43,500) 54,905 (27,026–94,731)
a Estimates are of deaths attributable specifically to foodborne transmission of these two pathogens.
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true for Shigella, which had more than twice the number of ill-
nesses among those over five compared those under five [14].
Year lost due to disability (YLD) and disability adjusted life-
years (DALY) data further demonstrate the burden of these two
pathogens. Colombara et al. concluded that both ETEC and Shigella
were among the top five enteric pathogens causing diarrhea-
associated YLDs [41]. GBD 2010 data indicate that a slightly greater
number of YLDs are attributable to ETEC than Shigella (15 per
100,000 vs 11 per 100,000), and that DALYS attributable to each
pathogen are relatively similar to each other (6,894,000 for ETEC
vs. 7,052,000 for Shigella). However, uncertainty intervals corre-
sponding to each pathogen overlap for both DALYS and YLDs
[3,42]. FERG attributed a greater number of DALYs to ETEC (30
(17–51) per 100,000) than Shigella (18 (83 7) per 100,000). Table 3
shows additional DALY and YLD data [14].
A systematic review by Fischer-Walker et al. in 2010 found that
ETEC was about twice as common as Shigella among inpatient cases
of diarrhea (14% vs 6.5% of cases, respectively) across all age
groups, while Shigella was about three times more common than
ETEC in outpatient settings (19.6% vs 5.9%, respectively) [43].
Among older children and adults, Lamberti et al. concluded that
the burden of morbidity and mortality associated with ETEC and
Shigella among those over five years old in Africa and South Asia
was substantial (19,451 deaths due to Shigella spp. and 42,973
due to ETEC in AFR, and 20,691 due to Shigella spp. and 45,713
due to ETEC in SEAR in 2010) [11]. An improved understanding
of the proportional distribution of inpatient vs outpatient cases
of Shigella and ETEC is needed to better inform burden assess-
ments, and to rationalize the most cost-effective vaccination
strategy.
To summarize, there has been significant deviation in various
iterations of the mortality estimates produced by the same groups,
as well as variances in the absolute estimates reported between
different groups. It is unclear which estimates are the most accu-
rate. This lack of clarity risks product development decision mak-
ing, and may ultimately jeopardize policy review for vaccine
introduction, since these are driven by burden of disease data.
2.2. Estimates derived from specific epidemiological studies
The Global Enteric Multi-center Study (GEMS) and the Etiology,
Risk Factors, and Interactions of Enteric Infections and Malnutri-
tion and the Consequences for Child Health and Development
(MAL-ED) are epidemiologic studies that gathered primary data
directly from high burden, low- income communities [9,12,44].
GEMS was a clinic-based, three-year, case-control study conducted
at seven sites in Africa and Asia that investigated moderate-to-
severe diarrhea (MSD) in children under five years [9]. Children
were also visited 2–3 months after enrolment. Three age strata
were evaluated: 0–11 months, 12–23 months and 24 – 59 months.
MAL-ED was a longitudinal community-based birth cohort
study conducted in 8 sites in Africa, Latin America and Asia that
analyzed pathogen-specific diarrheal burden in children between
0–11 months and 12–24 months. The differences in structure and
design of these two studies are important to consider when assess-
ing their results (Section 4), and have been discussed in a recent
review [45].
GEMS, which was conducted at sites that had not introduced
rotavirus vaccine, concluded that most attributable cases of
moderate-to-severe diarrhea were due to rotavirus, Cryptosporid-
ium, ST-producing ETEC (with or without LT), and Shigella, across
all study sites and in one or more age strata. The adjusted attribu-
table fraction (AF) of Shigella increased as age increased at every
site. ST-producing ETEC was a significant pathogen at every site
in at least one age stratum and in all age strata at four sites. It
was one of the pathogens most associated with risk of death in
the two months following diagnosis (Hazard Ratio 2.0, p = 0.03),
however there may be other factors that contributed to, or caused,
death between the initial diagnosis and the follow up visit 2
months later [9]. Conversely, ETEC producing LT alone was not a
significant cause of moderate-to-severe diarrhea at any site or in
age stratum. Of note, the median age of MSD cases with an ST-
ETEC infection was 14 months of age, whereas it was 6 months
later for Shigella at 20 months of age [46]. These findings may have
implications for the optimal immunization schedule of these
Table 2
Global Estimates of Deaths Among All Age Groups Combined.
Study FERG [14] GBD 2010 [2] GBD 2013 [39] GBD 2015 [1]
Year of publication 2015 2012 2015 2016
Time period of data
collection
1990–2012 1980–2010 1990–2013 1980–2015
Year represented in data 2010 2010 2013 2015
Geographical range of data 194 countries 187 countries 188 countries 195 countries and territories
Number of diarrhea causing
pathogens assessed
22 10 13 13
All-cause diarrheal deaths
(uncertainty range)
1,092,548 (892,999–
1,374,238)
a350,686 (240,030–524,042)
1,445,800 (1,278,900–
1,607,000)
1,264,100 (1,151,200–
1,383,200)
1,312,100 (1,233,600–
1,391,300)
Number of ETEC deaths
(uncertainty range)
73,857 (53,851–103,026)
a26,170 (14,887–43,523)
120,800 (95,700–147,600) 59,200 (44,200–77,700) 74,100 (29,900–137,900)
Number of Shigella deaths
(uncertainty range)
65,796 (46,317–97,036)
a15,156 (6,839–30,072)
122,800 (97,400–149,600) 73,900 (58,900–93,800) 164,300 (85,000–278,700)
a Estimates correspond to deaths specifically attributed to foodborne transmission of the pathogen.
Table 3
Reported YLD and DALY estimates.
Study Year
reported
in data
Age
group
Total ETEC YLDs [42] Total Shigella YLDs [42] Total ETEC DALYS [3] Total Shigella DALYS [3]
GBD 2010
(uncertainty range)
2010 All ages 1,065,000
(649,000–1,643,000)
744,000
(440,000–1,147,000)
6,894,000 (5,619,000–
8,286,000)
7,052,000(5,676,000–
8,466,000)
FERG 2010 All ages – – 5,887,541 (4,190,610–
8,407,186) [14]
5,407,736 (3,771,300–
8,107,456) [14]
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vaccines, and their fit within the Expanded Programme of Immu-
nization (EPI).
In line with the GEMS conclusions, MAL-ED found ST-producing
ETEC was more common than Shigella in the first year of life [12].
Higher proportions of ST-producing ETEC, compared to LT-
producing ETEC, were observed among diarrheal episodes in both
the first (1.9% vs 1.3%) and second (3.9% vs 1.2%) years of life, with
non-overlapping confidence intervals for ages 12–24 months. It
also reported that LT-producing ETEC, ST-producing ETEC and Shi-
gella were associated with persistent diarrhea [12]. MAL-ED attri-
butable fractions (AFs) for ST-producing ETEC among children
12–24 months with severe disease were more similar to those
reported in GEMS.
Both GEMS and MAL-ED have recently published updated anal-
yses using more sensitive quantitative molecular diagnostic assays
[47,48]. A recent reanalysis of GEMS samples, which included STp,
found that the AFs increased by about twofold for Shigella and 1.5-
fold for ST-ETEC, with Shigella showing the largest increase in the
second year of life [48]. However, between 2 and 3% of control
samples with both watery diarrhea and dysentery were infected
with Shigella in children over 11 months[46]. The change in the
assigned etiology following the GEMS reanalysis highlights the
impact on disease burden estimates of utilizing more sensitive
and specific analytical methodology for diagnosis. This is further
demonstrated by the MAL-ED study involving a subset of speci-
mens that were assessed using qPCR against 19 enteropathogens.
With qualitative PCR detection, no pathogens were significantly
associated with diarrhea, however quantitative analysis using
qPCR revealed that Shigella/enteroinvasive Escherichia coli infec-
tions (OR = 1.47, P = 0.04) were significantly associated with symp-
tomatic diarrhea [47].
Asymptomatic carriage among children without diarrhea was
found in both studies and has been observed with both conven-
tional and molecular diagnostic methods, particularly for LT-
producing ETEC in MAL-ED. For ST-producing ETEC, prevalence
was about twice as high in symptomatic cases compared to non-
diarrheal samples in each age cohort of MAL-ED. Interestingly,
while the Shigella prevalence was notably higher among diarrheal
samples compared with the non-diarrheal samples between 12
and 24 months of age in MAL-ED, the difference in prevalence nar-
rowed for the 12–23 month age cohort in GEMS (OR of 2.0 com-
pared to OR = 7.5 for the 0–11 month cohort) [46]. This indicates
that levels of asymptomatic carriage can fluctuate across age
groups and study settings, and is particularly confounding in LMIC
contexts, where children are often infected with multiple enteric
pathogens. Studies are ongoing to compare detected pathogen
loads, in terms of qPCR threshold cycle (Cq) values, and to stratify
these with respect to symptomatic and asymptomatic infections.
This approach may help to provide greater etiologic accuracy,
and is likely to result in further shifts in future disease burden
estimates.
These two studies exemplify how severe and less severe diar-
rheal diseases may have different distributions of etiologies, and
how case definition is critical to capture asymptomatic and mild
cases of disease. As discussed in Section 5, mild disease is also of
significant public health concern.
3. Variability in methodology across modelled estimates
3.1. Variation among the 2010, 2013 and 2015 GBD estimates
Some aspects of calculating etiologic-specific diarrheal esti-
mates for GBD have changed with each iteration of the estimates
[1,2,39]. The GBD 2010 pathogen-specific estimates for diarrheal
mortality used the International Classification of Disease approach
for establishing a single underlying pathogen as a cause of diar-
rheal death [1,39]. GBD 2013 and GBD 2015, instead, used a coun-
terfactual approach that considered the prevalence and risk of
disease for each diarrheal pathogen, similar to how risk factors
were calculated, and used GEMS-derived odds ratios to determine
the pathogen-specific attributable fractions [1,39]. GBD 2013 used
data from the original GEMS study. For countries not included in
the GEMS study, the mean odds ratios from nearby GEMS sites
were used, or an average of odds ratios from all sites were used
to determine etiology [39].
The GBD 2015 iteration incorporated data produced from the
more sensitive qPCR reanalysis of GEMS samples leading to higher
AFs for many pathogens compared to those in GBD 2013 [1,39,48].
GBD 2015 estimates incorporated the mean odds ratios of all GEMS
sites. Because most diarrheal etiology data used in other studies
included in GBD 2015 relied on less sensitive conventional meth-
ods, GBD 2015 calculations used a correction factor to adjust
prevalence estimates such that they became more comparable to
odds ratios from the GEMS reanalysis [1].
While the GEMS data affected global diarrheal burden estimates
in GBDs 2013 and 2015, not all trends observed in GEMS were
reflected in GBD estimates. For example, while the GEMS reanaly-
sis generally showed an increase in the ETEC AF, a comparable
increase in AF did not occur from GBD 2013 to GBD 2015 (4.7–
5.6% among all ages, respectively) [1,9,39,48]. Furthermore, the
AF for non-typhoidal Salmonella is higher than that of ETEC in
GBD 2015 (7.7% vs 4.7% children under five years, respectively),
but the AF from Salmonella spp. was lower than that of ETEC across
all age groups in GEMS studies [1,39]. Fully capturing the complex-
ities of developing recent GBD estimates goes beyond the scope of
our report, but could be one of the goals of future consultations or
working group discussions aimed at better understanding Shigella
and ETEC disease burden.
3.2. Variation among GBD and other modelled disease burden
estimates
Although structural differences between the GBD and CHERG/
MCEE models exist, data inputs likely contributed most to the vari-
ability between estimates [49]. While GBD used a mix of observa-
tional data from inpatient, outpatient, community-based and case-
control studies from data sources spanning several decades,
CHERG/MCEE used inpatient data from 1990 to 2011 [10].
Approaches used to account for co-infections also differed between
the two studies. Importantly, the most currently published
pathogen-specific diarrheal CHERG/MCEE estimates do not incor-
porate the GEMS derived odds ratios to determine pathogen speci-
fic AFs because GEMS did not distinguish between inpatient and
outpatient cases [1,10,49]. Further detail regarding the intricacies
of methodologies used by these studies is described in multiple
sources [2,10,39,49,50].
FERG based etiologic distribution of food-borne illness on inpa-
tient, outpatient and community research studies [14]. Like
CHERG/MCEE, results from systematic literature reviews were
used to estimate attributable fractions. FERG estimated the etiolog-
ical proportions associated with non-fatal illness for children
under five years based on the distribution of pathogens found in
the outpatient and community studies, whereas the distribution
of pathogens in inpatient settings was assumed to reflect the
pathogen prevalence among diarrheal deaths [14,51]. For people
over five years, inpatient studies in addition to outpatient or com-
munity studies were used to calculate pathogen prevalence among
cases, due to a lack of outpatient or community data in older pop-
ulations. Pathogens that were not commonly transmitted through
food, such as rotavirus, were aggregated as ‘other pathogens’,
hence rotavirus was not identified as a top cause of diarrhea in this
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study [51]. Similarly, Lamberti et al. used the distribution of patho-
gen etiology among hospitalized cases to determine the etiologic
proportions associated with pathogen-specific diarrheal mortality
[11,14]. Because ETEC may be more likely to be found in hospital-
ized patients than Shigella, the focus of these studies on using inpa-
tient data to estimate mortality could possibly underestimate
Shigella mortality [43]. Also, the incidence of Shigella is possibly
cyclical over the course of multiple years, contributing to a possible
waxing and waning of shigellosis hospitalization rates [52,53].
Lamberti et al. exclusively assessed Shigella and ETEC, rather than
all common diarrheal pathogens, which could contribute to poten-
tially higher estimates [11].
4. Factors that contribute to variation in disease burden and
attribution of etiology for both modelled and epidemiologic
estimates
The differences reported across the disease burden estimates
discussed, particularly in epidemiologic studies such as GEMS
and MAL-ED, are attributable to epidemiological setting, method-
ological differences in the detection and estimation methods, the
data available, as well as to changes in the total number of diar-
rheal deaths. Factors that influence the estimate outcome are dis-
cussed below.
4.1. Geographical variation
The studies and systematic reviews discussed above have ana-
lyzed data derived from different geographical and socio-
economic settings. GBD, FERG, and MCEE/CHERG analyses included
data from both low and high income countries [1,10,39]. A limita-
tion of all the systematic reviews is that case detection and surveil-
lance are lacking from many countries so that data from
surrounding or similar countries must be extrapolated.
Both GEMS and MAL-ED collected primary data from South
Asian and Sub-Saharan African LMICs, while MAL-ED also included
Latin American sites [9,12]. In general, the GEMS sites were in
more resource-limited areas than the MALED sites, which may
have increased exposure and susceptibility to other risks. In GEMS,
it was noted that the burden of Shigella at the site in Mirzapur, Ban-
gladesh was found to be particularly high, and approximately four
times that of the GEMS region with the next highest AF among
children in the second year of life (52.2% in Mirzapur vs 12.8% in
Basse, Gambia 12–23 mos.) [9]. The GEMS qPCR reanalysis con-
firmed this trend, and the AFs associated with most pathogens,
particularly Shigella, increased across almost all sites [48]. Interest-
ingly, the MAL-ED Dhaka site approximately 1000 km away from
Mirzapur had one of the lowest Shigella AFs among all the study
locations, suggesting substantial localized variation in incidence
[12]. Higher Shigella and ETEC incidence has been reported in the
EMR and AFR regions, respectively, underlying likely geographic
heterogeneity in burden [11,51,54]. Since these data may not be
broadly representative of the surrounding region, their inclusion
may introduce bias into the estimates, particularly if they are used
for extrapolation.
4.2. Case definition
There were differences in case ascertainment methods in the
GEMS and MAL-ED studies. The clinic-based GEMS study did not
distinguish inpatient and outpatient cases, [9,10] and its case def-
inition of MSD was designed to select for diarrheal disease that
may have been fatal in children under five years if left untreated
in the community. MAL-ED included both mild diarrhea and MSD
cases [12,55]. MAL-ED used a modified Vesikari score to assess
which pathogens were associated with particular symptoms and
severity levels [12]. Both studies included children with dysentery;
however, MAL-ED included children who had at least one stool
containing blood, while GEMS did not count cases that had fewer
than three stools, irrespective of blood [9,12]. The different inclu-
sion criteria and disease severity between the two studies is
important to consider when reviewing their conclusions.
4.3. Diagnosis
Diagnostic techniques vary in their ability to detect infectious
agents, therefore affecting attribution of diarrheal etiology. Ideally,
diagnostic tests for diarrheal illness in LMICs would be quantita-
tive, reliable, sensitive, specific, rapid, and accessible [56]. Cur-
rently, no diagnostic methods for ETEC and Shigella adhere to all
these criteria.
Shigella spp. are conventionally diagnosed by isolation on cul-
ture, subsequent standard biochemical testing, and serotyping via
serum agglutination [57,29,58]. ETEC infection is generally diag-
nosed by selecting suspected colonies from differential media
and using PCR to detect the presence of ETEC-specific genes, such
as those encoding LT or ST, or by using an ELISA [57–59]. These
methods tend to be more standardized and less dependent on
expensive equipment [57,58,60,61].
Conventional approaches, particularly involving cultures, can be
less sensitive than molecular techniques [61]. Isolating colonies of
particular pathogens from stool can be time consuming and diffi-
cult, especially if antibiotics were used or if pathogens, including
Shigella, are fastidious [26,60]. Both E. coli and Shigella spp. can also
remain in non-dividing states when cultured [62,63]. Assay accu-
racy and sensitivity can vary with bacterial load, or the number
of colonies selected [58,64]. The significant constraints and chal-
lenges of these conventional methods have driven the use of newer
PCR assays for pathogen identification.
Taqman Array Cards (TAC), and Loop-mediated Isothermal
Amplification (LAMP) are two examples of next-generation assays
that are being increasingly used for enteric diagnostics [65,66]. The
TAC qPCR platform has been used to reanalyze GEMS and MAL-ED
samples [47,48]. TAC involves arrayed singleplex reactions that can
run many small volume qPCRs against different pathogens simul-
taneously but separately, enabling a larger array of pathogens to
be tested [65,67]. These assays are also now increasingly being uti-
lized in disease surveillance. LAMP assays are isothermal nucleic
acid amplification tests that have been preliminarily tested in a
quantitative or semi-quantitative function and are highly specific
due to the use of several primers [66,68,69].
These newer molecular assays are generally much more sensi-
tive than conventional methods [70]. qPCR assays, such as TAC,
have an expanded range of genes to identify more specifically ETEC
colonization factors and Shigella serotypes, and can also be used to
quantify the amount of pathogen present, based on the number of
PCR amplification cycles (Cq) [60,70]. Thus, quantitative methods
can indicate the etiologic agent by detecting the most common
pathogen among several co-infecting microbes [60]. TAC and LAMP
are also generally less time consuming than conventional culture,
with LAMP complete in under one hour [69,71].
However, there are various challenges in selecting the optimal
detection methodology. Assay sensitivity can vary by pathogen
type, leading to possible bias when assessing particular pathogens
[26,67,72]. Additionally, stool has inhibitory components that can
interfere with DNA extraction and amplification [60,67,70]. Finally,
molecular assays tend to rely on materials that are impractical to
use in LMICs [66]. LAMP may eventually become an accessible
LMIC diagnostic, while regular use of qPCR may only be possible
in research settings or regional surveillance laboratories.
Importantly, laboratory procedures including primers, reagents,
and protocols need to be standardized across different laboratory
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settings to ensure comparable data [67,73]. Studies assessing these
molecular techniques have acknowledged that variation across
protocols leads to differing results [74]. For example, MAL-ED data
indicated that a one-unit difference in Cq cut-off led to at least a
3% change in attributable fraction for Shigella [47]. The high sensi-
tivity of TAC may increase the likelihood of detecting several co-
infecting organisms; thus, determining the Cq cut-off value that
is used to assign a specific disease etiology for each pathogen is
important [47].
4.4. Co-infection, asymptomatic infection, and infections of unknown
etiology
Establishing the etiology of diarrhea is complex due to the com-
mon presence of co-infections and asymptomatic carriage of
pathogens [48,60,75]. The MCEE/CHERG stratified analyses by sin-
gle as well as multi pathogen approaches because prior research
suggests that single pathogen studies tend to result in higher esti-
mates, though there is debate over the extent of these differences
[10,76]. GBD estimates did include single pathogen studies but
reported using discretion in assessing potential biases [10,43,76].
In multiple studies, almost half of the diarrheal cases had no
assignable cause, often due to a lack of information or to a possible
unassessed etiologic agent [14,39].
GEMS found that 72% of asymptomatic controls carried at least
one diarrheal pathogen, indicating that detecting the presence of a
pathogen may not be clinically relevant [9]. Regression methods
were used to find which pathogens were significantly associated
with diarrhea in cases, compared to controls, and the AF was calcu-
lated based on these analyses [9]. Shigella had a high AF because
about 90% of positive cases had diarrhea. Children infected with
ETEC producing ST exhibited higher rates of asymptomatic car-
riage, so only about 60–70% of those cases could be attributed to
that pathogen [9]. While original GEMS analyses involved estab-
lished Shigella or ETEC etiology using culture or multiplex PCR,
respectively, the qPCR reanalysis provided a more quantifiable
approach [48].
5. The long-term health consequences of diarrheal infections
While the estimates of disease burden previously discussed pri-
marily focused on mortality or diarrheal incidence, there are
increased efforts to quantify the long-term economic and health-
related effects of enteropathogens in order to better understand
the relationship between diarrhea and the perpetuation of poverty.
According to the World Bank, 1 in 10 people globally live in
extreme poverty, and over half of this population consists of young,
poorly educated communities in rural Sub-Saharan Africa [77]. A
lack of safe water and adequate sanitation facilitate high rates of
enteric infection, which can cause blunting of gut villi that impede
nutrient absorption leading to malnutrition, and indirect effects
such as growth stunting and inadequate immune responses and
to immunization [4,78]. Furthermore, data reviewed by Guerrant
et al. suggests that stunted growth in early childhood is a risk fac-
tor for cognitive impairment, as well as other co-morbidities such
as obesity, type 2 diabetes, metabolic syndrome and cardio vascu-
lar disease (CVD) later in life [4]. A recent publication suggests that
diarrhea is also associated with acute lower respiratory tract infec-
tion in young children, in LMICs [79]. Shigella and ETEC, in partic-
ular, have been significantly associated with reduced childhood
growth compared to other common pathogens such as rotavirus
[41,59,80].
A challenge with evaluating the impact of a vaccine on indirect,
long term sequelae of diarrhea is that measuring such effects can
require costly longitudinal studies that are often not practical for
vaccine trials [36,80–82]. While stunting is potentially associated
with a broad spectrum of morbidities, there are no validated
biomarkers or clinical diagnostic criteria to evaluate the causative
mechanisms [83]. It is therefore difficult to stratify the effects of
diarrhea, malnutrition, and stunting on long term health and eco-
nomic development. It is important to consider how to capture the
impact of these long-term to measure the entire burden of these
diseases, so that the full benefit that a vaccine may offer may be
measured. Further evaluation of the pathologic mechanisms by
which ETEC- and Shigella-associated diarrhea impact growth, cog-
nition, and future disease incidence may validate a proxy or corre-
late that will facilitate this.
6. The potential public health impact of a Shigella and ETEC
vaccine
The elements that influence the decision to introduce a vaccine
are based on (i) the public health need for the vaccine, i.e. its
potential to reduce both mortality and morbidity, in the context
of other available interventions, (ii) the characteristics of the vac-
cine, such as its safety and efficacy, as well as its cost-
effectiveness and (iii) the capacity of the immunization program
and the underlying health system to deliver the vaccine [84]. These
factors determine the evidence, or data, that will be required for a
policy review if these vaccines become licensed.
In addition to decreasing the mortality burden, a vaccine would
significantly reduce the large costs of treating diarrhea, and the
loss of productivity of adults when they or their children are ill
[34,85]. The rise in antibiotic resistance, particularly for the treat-
ment of Shigella, will likely increase the cost and complexity of
treatment regimens that would be obviated if an effective vaccine
were available. An important next step will be to further character-
ize and substantiate the potential health and socio-economic ben-
efits that vaccination could provide in order to better articulate the
potential vaccine impact, and strengthen the value proposition for
developing these vaccines [86]. To date, there have been studies
describing the economic value of ETEC and Shigella vaccines among
travelers and military from high income countries; however, these
study populations may not capture the effects of vaccination for
children in endemic countries [87]. An investment market assess-
ment on a vaccine for ETEC stand-alone vaccines suggested it
may present an estimated annual revenue potential of more than
$600 million, 10 years after global launch, based on primarily on
travelers and middle-income markets (both public and private),
but military and low-income markets were also represented [88].
Finally, it will be important to understand the timeline and proba-
bility of technical success for the various vaccine approaches, and
to model both the potential burden estimate and need for these
vaccines when programmatically suitable ETEC and Shigella vac-
cine combinations may become available.
7. Concluding remarks and recommended discussion points
The studies reviewed here substantiate that both Shigella and
ETEC cause acute and long-term health and economic conse-
quences. However, the point estimates of mortality differ between
iterations published by the same group, as well as between esti-
mates of different groups, although the uncertainty intervals are
broad and overlapping. It is unclear how much of the fluctuation
in estimates is a result of modifications to detection and modelling
methodology versus true changes in the number of deaths caused
by disease, and there is no consensus as to which estimates are the
most accurate or consistent going forward. In the interim, these
estimates are informing and impacting the prioritization of vaccine
candidates, and may result in the early termination of the develop-
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ment of a potentially effective vaccine. Better certainty is needed to
support decision making for investment decisions, and ultimately
vaccine introduction.
Both the GBD and MCEE estimates are currently undergoing
revision, and are expected to be published in late 2017. Since sev-
eral differences in the methodology of these two models remain,
they are unlikely to converge. For this reason, we believe that
broader discussion and investigation into the underlying reasons
for the uncertainties and ranges in mortality estimates are war-
ranted to help prioritize public health goals for these vaccines,
and ultimately guide policy decision making and vaccine introduc-
tion. We also would like to understand how the indirect morbidity
effects of diarrhea caused by these pathogens could be measured,
and how these could contribute to the cost-effectiveness assess-
ment of potential vaccines.
The following aspects are recommended as priority areas of
focus:
 Understanding the uncertainties and limitations in the mortal-
ity modelling methodologies that are currently available,
including the role that sensitive TAC analyses have played in
shaping diarrheal morbidity and mortality estimates;
 An improved understanding of the proportional distribution of
inpatient vs outpatient cases of Shigella and ETEC is needed to
better inform burden assessments and to rationalize the most
cost-effective vaccination strategy;
 Assessment of long-term morbidity and socio-economic impact
of ETEC and Shigella diarrhea and potential impact of vaccina-
tion in low-income pediatric populations;
 The difference in timeline and development cost; risk (including
probability of technical success) and eventual uptake of ETEC
and Shigella vaccine candidates; and the mortality and morbid-
ity burden within this intervening period to facilitate
prioritization;
 Assessment of global ETEC and Shigella surveillance to improve
the epidemiological understanding of ETEC and Shigella diar-
rheal disease burden, particularly considering potential geo-
graphical heterogeneity and antigenic variation of circulating
strains;
 An important next step will be to further characterize and sub-
stantiate the potential health and socio-economic benefits that
vaccination could provide in order to better articulate the
potential vaccine impact, and strengthen the value proposition
for developing these vaccines.
Convergence on these issues is critical as the current ETEC and
Shigella vaccines advance to late stage clinical development, to
inform effective decision making for future enteric vaccine devel-
opment. As an initial next step, WHO convened a global consulta-
tion to better understand the status and challenges of determining
of ETEC and Shigella burden of disease estimates, and the strategic
direction of vaccine development against these antigens.
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